| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9498445 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) | |
| US9603806 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) | |
| US9050263 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) | |
| US11135172 | REDHILL | Rifabutin-based compositions and methods for treating Helicobacter pylori infection |
Feb, 2034
(10 years from now) | |
| US10238606 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) | |
Talicia is owned by Redhill.
Talicia contains Amoxicillin; Omeprazole Magnesium; Rifabutin.
Talicia has a total of 5 drug patents out of which 0 drug patents have expired.
Talicia was authorised for market use on 01 November, 2019.
Talicia is available in capsule, delayed release;oral dosage forms.
Talicia can be used as treatment of h. pylori infection in adults.
The generics of Talicia are possible to be released after 12 February, 2034.
Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Treatment of h. pylori infection in adults
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TALICIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic